SLC5A2 and diabetes mellitus: Considering the well-established effects and strong recommendation for SGLT2-inhibitors in HF,34 many patients with concomitant pre-diabetes and DM, both known and unknown, will receive SGLT2-inhibitor treatment as an added benefit.